ArticleEClinicalMedicine2026
Concordance and prognostic value of bone-marrow MRD and PET-CT in multiple myeloma: a systematic review and meta-analysis.
Article in EClinicalMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bone-marrow minimal residual disease (MRD) and positron emission tomography/computed tomography (PET-CT) are central to response assessment in multiple myeloma (MM); however, their agreement, discordant patterns, and how their joint results relate to progression-free survival have not been systematically quantified. Methods: We conducted a systematic review and random-effects meta-analysis, and searched PubMed and Cochrane CENTRAL from Jan 2015 to Sept 30, 2025, with an updated search to Jan 31, 2026. We included studies reporting paired MRD and PET-CT assessments, and, when available, progression-free survival (PFS), in patients with MM. Study-level 2 × 2 MRD/PET-CT tables (each test positive or negative) were abstracted or reconstructed from published counts or percentages. Primary outcomes were (1) cross-modality agreement (observed agreement and Cohen's κ) and directional discordance (log-odds of MRD Findings: Ten cohorts contributed 1138 paired MRD/PET-CT assessments. The joint 2 × 2 distribution was: (a) MRD Interpretation: MRD and PET-CT interrogate distinct but complementary disease compartments, yielding low statistical concordance yet strong joint prognostic value. Dual MRD/PET-CT negativity reproducibly identifies a low-risk subgroup, whereas discordant patterns capture biologically heterogeneous residual disease. Prospective myeloma trials should prespecify all four MRD/PET-CT categories, align assessment timing and thresholds, and routinely report concordance and discordance to enable response-adapted treatment. Funding: None.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.